Specifically, we queried the MSK-MET (pan-cancer cohort of 25,775 samples) (18) and MSK-CHORD (breast cancer cohort of 5,368 samples) (19) datasets through cBioPortal (https://www.cbioportal.org/) to identify relevant FGFR3-activating mutations. This evidence concerns the gene FGFR3 and breast carcinoma.